@article{6c423211e28447b19c154b2f40ac2b99,
title = "Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation",
abstract = "In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.",
author = "Uy, {G. L.} and Costa, {L. J.} and Hari, {P. N.} and Zhang, {M. J.} and Huang, {J. X.} and Anderson, {K. C.} and Bredeson, {C. N.} and Callander, {N. S.} and Cornell, {R. F.} and Perez, {M. A.D.} and A. Dispenzieri and Freytes, {C. O.} and Gale, {R. P.} and A. Garfall and Gertz, {M. A.} and J. Gibson and M. Hamadani and Lazarus, {H. M.} and Kalaycio, {M. E.} and Kamble, {R. T.} and Kharfan-Dabaja, {M. A.} and Krishnan, {A. Y.} and Kumar, {S. K.} and Kyle, {R. A.} and Landau, {H. J.} and Lee, {C. H.} and A. Maiolino and Marks, {D. I.} and Mark, {T. M.} and R. Munker and T. Nishihori and Olsson, {R. F.} and M. Ramanathan and Rodriguez, {T. E.} and Saad, {A. A.} and Savani, {B. N.} and Schiller, {G. J.} and Schouten, {H. C.} and Schriber, {J. R.} and E. Scott and S. Seo and M. Sharma and S. Ganguly and Stadtmauer, {E. A.} and J. Tay and To, {L. B.} and Vesole, {D. H.} and Vogl, {D. T.} and Wagner, {J. L.} and B. Wirk and Wood, {W. A.} and A. D'Souza",
note = "Funding Information: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children{\textquoteright}s Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick{\textquoteright}s Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. Publisher Copyright: {\textcopyright} 2015 Macmillan Publishers Limited.",
year = "2015",
month = dec,
day = "1",
doi = "10.1038/bmt.2015.190",
language = "English (US)",
volume = "50",
pages = "1513--1518",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",
}